Clinical-stage medical technology company Baronova has secured $27.3m from Series C financing round. The financing, which is led by investments from Sante Ventures and Boston Scientific, will be used by the company to fund a pivotal study ...
Tags: medical technology, weight loss technology, outpatient procedure
US-based medical technology provider Boston Scientific said it is launching the new polymer-based drug-eluting stent (DES) system in the European market as the product has obtained CE mark approval. The Promus Premier everolimus-eluting ...
Analog semiconductor maker Skyworks Solutions Inc of Woburn, MA, USA, has reported improved results for fiscal first-quarter 2013 (ending 28 December 2012). Revenue was $453.7m, up nearly 8% on last quarter’s $421.1m and 15% on ...
Boston Scientific has treated the first US patient with symptomatic, drug refractory paroxysmal atrial fibrillation in ZERO AF clinical trial of its Blazer Open-Irrigated Temperature Ablation Catheter. The Blazer Open-Irrigated Catheter ...
Network World - As of June 2012, there were 237,000 iPad apps listed in the App store, many of them priced at 99 cents or even free. Yet very few of them let companies actually do business -- take customer orders, update inventory, submit ...
Tags: iPad apps, App store, IT groups, IT industry
Boston Scientific has implanted the first patient with a new version of its Ingevity pacing leads, designed for use in the magnetic resonance imaging (MRI) environment, in a clinical study. The pacing leads, which are expected be paired ...
Biosensors International Group has completed enrolling the first patient in its polymer-free drug-coated stent's (DCS) clinical trial, designed to compare the safety of the BioFreedom with a bare-metal stent (BMS). Designed for use in ...
Medifocus, a developer of adaptive phased array technology, has purchased all the assets of Boston Scientific's Prolieve device business for $5m. The assets include all Prolieve inventory, the Rocky Mountain Mobile Services mobile ...
Tags: Medifocus, medical technology, acquisition
Boston Scientific has obtained CE mark approval for its Synergy Everolimus-Eluting platinum chromium coronary stent system, designed to improve post-implant vessel healing. The coronary stent, which features a combination of ...
The revised product labelings of Boston Scientific's Incepta, Energen, Punctua, Cognis and Teligen implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds) have been cleared by the US Food ...
Tags: FDA, medical technology, medical application
Boston Scientific has completed enrolling first patient in REPRISE II clinical trial, designed to assess the safety and efficacy of the Lotus Valve system in minimizing aortic regurgitation (leaking). The Lotus Valve system, which the ...
Tags: Boston Scientific, first patient, REPRISE II clinical trial
The US Food and Drug Administration (FDA) has cleared the expanded use indication of Boston Scientific's CRE Wireguided Balloon Dilator. The new indication facilitates physicians to perform dilation assisted stone extraction (DASE) of ...
Boston Scientific has launched Victory guidewire, designed to provide access to cross and treat resistant lesions in the US and Europe. The company said resistant lesions are characterized by blockage or narrowing of blood vessels in the ...
Tags: Victory guidewire, Boston Scientific, resistant lesions
Boston Scientific has received the US Food and Drug Administration (FDA) approval for 32 mm and 38 mm lengths of the Promus Element Plus Everolimus-Eluting Platinum Chromium Coronary Stent system. The Promus Element Stent is made with a ...
Tags: FDA, Boston Scientific, Promus Element Stent, coronary artery disease
Boston Scientific has entered into a definitive agreement to buy all the assets of Vessix Vascular for an upfront payment of $125m. Under the acquisition, Vessix Vascular will be integrated into Boston Scientific's peripheral ...